BOSTON--(BUSINESS WIRE)--Rounding out a year of tremendous growth on two continents, Dewpoint Therapeutics, the biomolecular condensates company, has been recognized by FierceBiotech as one of 2019’s most promising private biotechs.
“This year has seen unrivalled scientific talent in the early-stage life sciences world and it has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress, and panache,” said Ben Adams, Senior Editor of FierceBiotech.
2019 also been an exciting year for Dewpoint, which launched in January with an ambitious aim: harness the emerging science of biomolecular condensates to discover drugs for a wide range of important, once-intractable diseases. Building on the research of Dewpoint’s founders—Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and Richard Young of the Whitehead Institute in Cambridge, MA—Dewpoint scientists are working in the company’s new labs in Boston and Dresden to translate what has until now been a fascinating area of academic science into a powerful new tool for drug discovery.
“We are thrilled to see Dewpoint honored with a Fierce 15 award,” said Amir Nashat, Dewpoint CEO and a partner at Polaris Partners, which led Dewpoint's $60 million Series A financing round. “It's a reflection of the work of the company's deeply committed, experienced, and diverse team, as well as its pioneering application of condensate biology, which has the potential to transform how the industry develops drugs for diseases of critical unmet need.”
“We’re all excited to be building an organization capable of translating these incredible new biological insights into actionable drug-discovery methods and novel therapeutics,” said Dewpoint COO Bruce Beutel. “I’m extremely proud of the way we have been able to combine our Dresden team, who joined us with deep academic expertise in condensates, with our Boston team, which collectively has almost 200 years of industry experience, to create one cohesive condensate-focused drug discovery engine.”
Dewpoint now has around 25 employees between its two sites and is continuing to grow in both the U.S. and Germany.
About Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates—including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists are working in Boston, MA, and Dresden, Germany, to harness these discoveries to create treatments for the toughest diseases. Learn more at dewpointx.com.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.